Radius Health (RDUS) PT Raised to $52 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- S&P 500, Nasdaq eye tepid open as Middle East tensions weigh
- Fed’s Waller open to September rate hold—if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Radius Health (RDUS) PT Raised to $45 at Jefferies
December 23, 2014 8:05 AM ESTJefferies analyst Eun Yang boosted his price target on Buy-rated Radius Health (NASDAQ: RDUS) to $45.00 (from $26.00) after as successful Phase 4 for Abaloparatide-SC.
Yang commented, "Ph3 for ABL in osteoporosis hit all endpoints of study for regulatory approval & for potential advantages (vs. Forteo, $1.25B in... More
Radius Health (RDUS) Reports Positive Top-Line Abaloparatide-SC Phase 3 Data
December 22, 2014 6:42 AM ESTRadius Health (Nasdaq: RDUS) announced positive top-line 18-month fracture results from the Company's Phase 3 clinical trial (ACTIVE) evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis.
On the primary endpoint, the investigational drug abaloparatide-SC (n=690, fracture rate 0.72%) achieved a statistically significant 83% reduction of incident vertebral fractures as compared to the placebo-treated group (n=711, fracture rate 4.36%)... More
